A. Dobi

发表

Prostate cancer: Diagnostic performance of the PCA3 urine test

S. Srivastava, George Leighton Lee, A. Dobi, 2011, Nature Reviews Urology.

Silencing of lactotransferrin expression by methylation in prostate cancer progression

V. Srikantan, S. Srivastava, I. Sesterhenn, 2007, Cancer biology & therapy.

A Role for DNA Methylation in Regulating the Growth Suppressor PMEPA1 Gene in Prostate Cancer

S. Srivastava, Hongyun Li, M. Ehrich, 2007, Epigenetics.

Clinical potential of the ERG oncoprotein in prostate cancer

Isabell A. Sesterhenn, David G. McLeod, S. Srivastava, 2012, Nature Reviews Urology.

Synthesis of a gene for human serum albumin and its expression in Saccharomyces cerevisiae.

I. Cserpán, A. Dobi, A. Simoncsits, 1990, Nucleic acids research.

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation

S. Srivastava, I. Sesterhenn, I. Sesterhenn, 2008, Oncogene.

Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer

Jeonifer M. Garren, S. Srivastava, E. Diamandis, 2017, Journal of molecular biomarkers & diagnosis.

Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens

T. Werner, I. Sesterhenn, M. Seifert, 2008, Prostate Cancer and Prostatic Diseases.

Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer

S. Srivastava, H. Geng, M. Venkatachalam, 2019, Genes & cancer.

Anterior tumors of the prostate: clinicopathological features and outcomes

I. Sesterhenn, A. Dobi, J. Cullen, 2013, Prostate Cancer and Prostatic Disease.

The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma

D. Ornstein, S. Srivastava, I. Sesterhenn, 2009, The Prostate.

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Anne E. Calvaresi, P. Carroll, A. M. López, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2020, Journal of Translational Medicine.

Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression

Thomas L. Fillmore, Richard D. Smith, S. Srivastava, 2020, Cancers.

Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription.

H. Pollard, M. Srivastava, Y. Torosyan, 2006, Cancer research.

Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers

S. Srivastava, I. Sesterhenn, Hua Li, 2021, Frontiers in Oncology.

Prostate cancer marker panel with single cell sensitivity in urine

S. Srivastava, I. Sesterhenn, G. Petrovics, 2015, The Prostate.

Differences in the frequency of ERG oncoprotein expression between index tumors of Caucasian American and African American prostate cancer patients

S. Srivastava, S. Perner, D. Pfister, 2012 .

A Feedback Loop between the Androgen Receptor and a NEDD4-binding Protein, PMEPA1, in Prostate Cancer Cells*

S. Srivastava, Hongyun Li, D. Mcleod, 2008, Journal of Biological Chemistry.

Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells

C. Paweletz, H. Pollard, X. Leighton, 2010, Oncogene.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

V. Srikantan, J. Moul, S. Srivastava, 2006, Oncogene.

Monoklonale ERG-Antikörper

S. Srivastava, A. Dobi, Shyh-Han Tan, 2010 .

ERG anticorps monoclonaux

S. Srivastava, A. Dobi, Shyh-Han Tan, 2010 .

Far‐upstream elements are dispensable for tissue‐specific proenkephalin expression using a Cre‐mediated knock‐in strategy

D. Agoston, B. Sauer, A. Dobi, 2003, Journal of neurochemistry.

A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland

C. Bieberich, A. Dobi, C. Shashikant, 2009, Proceedings of the National Academy of Sciences.

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN

S. Srivastava, I. Sesterhenn, Hua Li, 2015, Oncotarget.

Mammalian expression cloning of nucleic acid binding proteins by agarose thin-layer gelshift clone selection.

C. Dalgard, A. Dobi, A. Owusu, 2002, BioTechniques.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression

T. Werner, V. Srikantan, I. Sesterhenn, 2012, Prostate Cancer and Prostatic Diseases.

ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma

A. Paetau, S. Srivastava, I. Sesterhenn, 2011, The American journal of surgical pathology.

Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody

C. Bieberich, V. Vasioukhin, S. Srivastava, 2010, Journal of Cancer.

PMEPA1 Gene Isoforms: A Potential Biomarker and Therapeutic Target in Prostate Cancer

S. Srivastava, Hua Li, A. Srinivasan, 2020, Biomolecules.

Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer

Z. Szallasi, S. Srivastava, Hua Li, 2019, Cancers.

Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival

S. Srivastava, Y. Shi, D. Mcleod, 2006, Oncogene.

Isolation and Characterization of SATB2, a Novel AT-rich DNA Binding Protein Expressed in Development- and Cell-Specific Manner in the Rat Brain

C. Paweletz, D. Agoston, Andrea B. Gyorgy, 2006, Neurochemical Research.

Sample and probe: a novel approach for identifying development-specific cis-elements of the enkephalin gene.

M. Palkovits, D. Agoston, A. Dobi, 1997, Brain research. Molecular brain research.

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence

S. Srivastava, I. Sesterhenn, S. Srivastava, 2019, Oncotarget.

Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer

Yixue Li, S. Srivastava, Guo-Ping Zhao, 2018, Scientific Reports.

Ethnicity and ERG frequency in prostate cancer

S. Srivastava, A. Dobi, Jason Sedarsky, 2018, Nature Reviews Urology.

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

S-H Tan, S. Srivastava, I. Sesterhenn, 2010, Prostate Cancer and Prostatic Diseases.

Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2008, Modern Pathology.

Detection of conformation bias between the complementary strands of deoxynucleotide repeat (TG/AC)n

D. Agoston, A. Dobi, Mark A. Mahan, 1997, Electrophoresis.

Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with distinct homologous recombination deficiency associated DNA aberration profiles

Z. Szallasi, I. Csabai, G. Klus, 2021, medRxiv.

Isolation and structural and genetic analysis of the mouse enkephalin gene and its d(AC/TG)n repeats.

A. Dobi, E. Santha, D. v Agoston, 1998, DNA sequence : the journal of DNA sequencing and mapping.

A Urine Exosome Gene Expression Panel Distinguishes Between Indolent and Aggressive Prostate Cancers at Biopsy.

S. Srivastava, I. Sesterhenn, S. Srivastava, 2020, The Journal of urology.

Prognostic features of Annexin A2 expression in prostate cancer.

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2020, Pathology.

ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer—a comparative study of two monoclonal antibodies

G. Kristiansen, G. Kristiansen, D. Goltz, 2012, Prostate Cancer and Prostatic Diseases.

ERG oncogene modulates prostaglandin signaling in prostate cancer cells

S. Srivastava, I. Sesterhenn, Hua Li, 2011, Cancer biology & therapy.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

V. Srikantan, J. Moul, S. Srivastava, 2005, Oncogene.

ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer

L. Bubendorf, S. Srivastava, I. Sesterhenn, 2014, Prostate Cancer and Prostatic Disease.

Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer

Chen Sun, S. Srivastava, I. Sesterhenn, 2008, Clinical Cancer Research.

ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men

S. Srivastava, I. Sesterhenn, Baohong Jiang, 2019, Journal of Cancer.

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men

Z. Szallasi, M. Loda, I. Csabai, 2015, EBioMedicine.

Evaluation of Androgen Receptor Function in Prostate Cancer Prognosis and Therapeutic Stratification

A. Dobi, 2014 .

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer

S. Srivastava, I. Sesterhenn, Hua Li, 2014, Epigenetics.

ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.

S. Srivastava, I. Sesterhenn, R. Pathmanathan, 2015, Molecular and clinical oncology.

Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma

S. Srivastava, J. Kulka, A. Szendrői, 2013, International Urology and Nephrology.

Androgen-Dependent Oncogenic Activation of ETS Transcription Factors by Recurrent Gene Fusions in Prostate Cancer: Biological and Clinical Implications

S. Srivastava, A. Dobi, T. Sreenath, 2013 .

Oncogenic activation of ERG: A predominant mechanism in prostate cancer

S. Srivastava, G. Petrovics, A. Dobi, 2011, Journal of carcinogenesis.

ERG Expression Levels in Prostate Tumors Reflect Functional Status of the Androgen Receptor (AR) as a Consequence of Fusion of ERG with AR Regulated Gene Promoters

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2010 .

Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors

T. Nikolskaya, Y. Nikolsky, T. Serebryiskaya, 2015, Journal of Cancer.

Evaluation of ERG responsive proteome in prostate cancer

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2014, The Prostate.

Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.

J. Strovel, S. Srivastava, C. Dalgard, 2018, Cancer research.

Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells

S. Srivastava, Hua Li, E. Srivatsan, 2017, Molecular Cancer Research.

New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives

S. Srivastava, A. Dobi, Mallesh Pandrala, 2021, ACS medicinal chemistry letters.

Genomic alterations of Tenascin C in highly aggressive prostate cancer: a meta-analysis

M. Kiebish, A. Srinivasan, Prachi Mishra, 2019, Genes & cancer.

M. Nevalainen, C. Bieberich, V. Vasioukhin, 2017, Scientific Reports.

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag

S. Srivastava, I. Sesterhenn, S. Srivastava, 2016, Genes & cancer.

Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1

S. Srivastava, G. Petrovics, A. Dobi, 2016, Oncotarget.

ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer

Nicholas B. Griner, S. Srivastava, I. Sesterhenn, 2014, Molecular Cancer Research.

ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer

S. Srivastava, I. Sesterhenn, J. Vishwanatha, 2014, Molecular Cancer Research.

miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT

H. Kung, J. Yang, C. Evans, 2014, Oncogene.

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer

S. Srivastava, G. Petrovics, A. Dobi, 2014, BMC Cancer.

Prostate cancer gene expression signature of patients with high body mass index

Hua Li, Yongmei Chen, G. Petrovics, 2010, Prostate Cancer and Prostatic Diseases.

Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression

Cara C. Schafer, J. Moul, S. Srivastava, 2022, Scientific Reports.

Ikaros is expressed in developing striatal neurons and involved in enkephalinergic differentiation

M. Palkovits, D. Agoston, Andrea B. Gyorgy, 2007, Journal of neurochemistry.

Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine.

C. Shriver, C. Turner, V. Giri, 2021, The Canadian journal of urology.

The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research.

S. Srivastava, G. Petrovics, A. Dobi, 2009, Urologic oncology.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression

T. Werner, V. Srikantan, S. Srivastava, 2011, Prostate Cancer and Prostatic Diseases.

Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes

S. Srivastava, I. Sesterhenn, H. Pollard, 2022, Nature Communications.

Submillimolar levels of calcium regulates DNA structure at the dinucleotide repeat (TG/AC)n.

A. Dobi, D. v Agoston, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase

V. Srikantan, J. Rhim, S. Srivastava, 2007, Prostate Cancer and Prostatic Diseases.

Androgen receptor and prostate cancer

S. Srivastava, A. Dobi, E. Richter, 2007, Prostate Cancer and Prostatic Diseases.

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

S. Srivastava, I. Sesterhenn, S. Perner, 2012, Urology.

Septamer Element-Binding Proteins in Neuronal and Glial Differentiation

M. Palkovits, A. Dobi, C. G. Palkovits, 2000, The Journal of Neuroscience.

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods

Richard D. Smith, S. Srivastava, D. Camp, 2015, Journal of Translational Medicine.

Cancer Genome Methylation: Biology, Biomarker and Therapeutic Opportunities

S. Srivastava, A. Dobi, T. Sreenath, 2017 .

AUF1 Is Expressed in the Developing Brain, Binds to AT-rich Double-stranded DNA, and Regulates Enkephalin Gene Expression*

M. Palkovits, D. Agoston, Andrea B. Gyorgy, 2006, Journal of Biological Chemistry.

Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome.

S. Srivastava, Kee-Hong Kim, S. Shaheduzzaman, 2008, Cancer biology & therapy.

Androgen receptor binding sites identified by a GREF_GATA model.

Matthias Frisch, Thomas Werner, T. Werner, 2005, Journal of molecular biology.

Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2017, European urology focus.

Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at Prostatectomy

S. Srivastava, M. Freedman, Yongmei Chen, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Protein-DNA interactions during phenotypic differentiation

M. Palkovits, D. Agoston, A. Dobi, 1995, Molecular Neurobiology.

Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens.

Cara C. Schafer, S. Srivastava, I. Sesterhenn, 2023, Journal of immunological methods.

Distinct Regions of Cu(I)·ACE1 Contact Two Spatially Resolved DNA Major Groove Sites(*)

D. Hamer, D. Winge, Stella Hu, 1995, The Journal of Biological Chemistry.

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2020, Journal of Translational Medicine.

M. Nevalainen, C. Bieberich, V. Vasioukhin, 2017, Scientific Reports.

Complexity of transcriptional control in neuropeptide gene expression; enkephalin gene regulation during neurodevelopment.

D. Agoston, A. Dobi, 2000, Biochemical Society transactions.

Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome

S. Srivastava, Kee-Hong Kim, S. Shaheduzzaman, 2008 .

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer

S. Srivastava, I. Sesterhenn, S. Srivastava, 2014, Genes & cancer.

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer

S. Srivastava, G. Petrovics, A. Dobi, 2014, BMC Cancer.

Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men

S. Srivastava, G. Petrovics, A. Dobi, 2023, Biomedicines.

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Jeonifer M. Garren, S. Srivastava, E. Diamandis, 2021, Scientific Reports.

Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer

Yixue Li, S. Srivastava, Guo-Ping Zhao, 2018, Scientific Reports.

ERG Expression Levels in Prostate Tumors Reflect Functional Status ofthe Androgen Receptor (AR) as a Consequence of Fusion of ERG with ARRegulated Gene Promoters

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2010 .

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods

Richard D. Smith, S. Srivastava, D. Camp, 2015, Journal of Translational Medicine.

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African

S. Srivastava, M. Freedman, I. Sesterhenn, 2018 .

Ikaros is expressed in developing striatal neurons and involved in enkephalinergic differentiation

M. Palkovits, D. Agoston, Andrea B. Gyorgy, 2007, Journal of neurochemistry.

Emerging Developments in ETS-Positive Prostate Cancer Therapy.

A. Dobi, Binil Eldhose, Gartrell C. Bowling, 2022, Molecular cancer therapeutics.

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials

A. Dobi, Binil Eldhose, Gartrell C Bowling, 2023, Cancers.